deferoxamine


Also found in: Acronyms, Wikipedia.

deferoxamine

 [de″fer-oks´ah-mēn]
an iron-chelating agent isolated from Streptomyces pilosus, used as an antidote in iron poisoning.

deferoxamine

Deferoxamine mesylate Hematology A trihydroxamic acid produced by Streptomyces pilosus that ↑ urinary iron excretion; it is the only FDA-approved iron-chelating agent for clinical use; early use of deferoxamine in thalassemia major ↓ transfusion-related iron overload and protects against DM, cardiac disease, early death. See Hemochromatosis.

deferoxamine

A chelating agent used to treat iron compound poisoning. The drug is on the WHO official list.
References in periodicals archive ?
Effects of Quercetin as Compared to Deferoxamine on Small Intestinal Iron Levels in Iron Overloaded Rats.
Xi, "Deferoxamine reduces cavity size in the brain after intracerebral hemorrhage in aged rats," in Intracerebral Hemorrhage Research, vol.
Nishino, "Treatment with deferoxamine increases neurons from neural stem/progenitor cells," Brain Research, vol.
Risk factors for HCV infection other than blood transfusion in [beta]-TM patients Characteristic HCV-infected HCV-not p patients (%) infected (%) value Surgery 44.7 55.3 0.062 Deferoxamine 38.4 61.6 0.58 intake Splenectomy 54.8 45.2 0.004 Family history of 37.5 62.5 0.76 [beta]-TM Gender Male 33.3 66.7 0.83 Female 34.6 65.4 Discussion
The results are presented in two separated categories for deferoxamine injection and blood transfusion.
The team used two FDA-approved iron chelators, deferoxamine and deferasirox, that can remove excess iron from the system by binding to the metal in a process called chelation.
The study is a follow-up to a 1-year, randomized, open-label, phase II trial that evaluated the safety and tolerability of deferasirox, given once daily as a dispersed solution in water, versus those of deferoxamine, given as a subcutaneous infusion in adults and children.
In the 1-year trial, the initial doses of deferasirox and deferoxamine were assigned according to patients' baseline liver iron concentration.
The analysis included data on 1,033 patients, including 330 who were in a crossover cohort of patients previously treated with deferoxamine.
Exclusion criteria were chronic hepatitis virus B or C infection, treatment with deferoxamine, or blood donation before hemochromatosis diagnosis.
Deferoxamine mesylate Abbott Laboratories Desferal for
* Deferoxamine (acute and chronic iron) causes toxicity in two animal species, but human pregnancy experience is substantial, and no embryonic or fetal adverse effects attributable to the agent have been reported.